Adma Biologics (ADMA) closed the most recent trading day at $6.74, moving +1.05% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.91%.

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of its three marketed ...

All three small-cap biotech/biopharma stocks have attractive risk/reward profiles and potential catalysts on the horizon.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock ...

Bristol-Myers Squibb Company (NYSE: BMY) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus ...

In the latest market close, Adma Biologics (ADMA) reached $6.44, with a -0.31% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.46%.

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key ...

There are several stocks that passed through the screen and Adma Biologics (ADMA) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid price ...

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the ...

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the ...